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9%, respectively. The frequency of isolates with ESBLs (2016-
2017) was: 30.5% K. pneumoniae, 8.6% E. coli, 2.3% Klebsiella 
oxytoca and 0.7% Proteus mirabilis. Ceftolozane-tazobactam 
was very active against non-ESBL-(99.3% susceptible) and 
ESBL-(95.2%) producing E. coli being less active against K. 
pneumoniae (98% and 43.1%, respectively) isolates. CTX-M-15 
was the most prevalent ESBL in E. coli (27.5%) and K. pneumo-
niae (51.9%) frequently associated with OXA-48-like carbap-
enemase. Overall, 93% of P. aeruginosa isolates were suscepti-
ble to ceftolozane-tazobactam, preserving this activity (>75%) 
in isolates resistant to other beta-lactams except in those re-
sistant to meropenen or ceftazidime-avibactam. GES-5, PER-1, 
VIM-1/2 were the most prevalent enzymes in isolates resistant 
to ceftolozane-tazobactam.
Conclusions. Ceftolozane-tazobactam showed high ac-
tivity rates against isolates recovered in the SMART study al-
though it was affected in K. pneumoniae and P. aeruginosa 
isolates with ESBL and/or carbapenemases.
Key words: Ceftolozane-tazobactam, Enterobacterales, Pseudomonas aeru-
ginosa, surveillance study. 
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ABSTRACT 
Objective. To analyse the susceptibility to ceftolo-
zane-tazobactam and comparators in Enterobacterales and 
Pseudomonas aeruginosa isolates recovered from intraabdom-
inal (IAI), urinary (UTI), respiratory (RTI) and bloodstream infec-
tion (BSI) in the SMART (Study for Monitoring Antimicrobial 
Resistance Trends) study.
Methods. The susceptibility of 5,351 isolates collect-
ed in 11 Spanish hospitals (2016-2018) were analysed 
(EUCAST-2020 criteria) by broth microdilution and were phe-
notypically studied for the presence of extended-spectrum be-
ta-lactamases (ESBL). Ceftolozane-tazobactam and/or carbap-
enem resistant isolates were genetically characterized for ESBL 
and carbapenemases.
Results. Escherichia coli was the most frequent pathogen 
(49.3% IAI, 54.9% UTI, 16.7% RTI and 50% BSI), followed by 
Klebsiella pneumoniae (11.9%, 19.1%, 13.1% and 15.4%, re-
spectively). P. aeruginosa was isolated in 9.3%, 5.6%, 32% and 
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on Antimicrobial Resistance of the United Nations [5] and 
the European One Health Action Plan against Antimicrobial 
Resistance from the European Commission [6], have delineat-
ed the strategies to address this problem. All of them agree 
not only to establish or to improve antimicrobial stewardship 
programs, hygiene, sanitation and infection control practices, 
to reduce the antimicrobial use and to increase the research 
on new antimicrobial drugs but also to intensify our efforts on 
surveillance. Surveillance programs are delineated to monitor 
antimicrobial use and resistance trends, to detect the emer-
gence of new resistance mechanisms, to measure the impact 
of the introduction of new drugs into the antimicrobial arma-
mentarium and to better use these compounds empirically. 
The Study for Monitoring Antimicrobial Resistance 
Trends (SMART) is a world-wide surveillance program creat-
ed in 2002 to monitor trends of antimicrobial susceptibility of 
aerobic and facultative Gram-negative bacilli from intra-ab-
dominal infections (IAIs) with special attention on ertapenem 
and extended-spectrum beta-lactamases (ESBLs) producing 
Enterobacterales [7]. The objectives were expanded to in-
clude isolates recovered from urinary tract infections (UTIs) 
in 2009, lower respiratory tract infections (RTI) in 2015 and 
bloodstream infections (BSI) in 2018. Moreover, it is now al-
so focused on carbapenem resistance and carbapenemases in 
Enterobacterales and multidrug resistance in Pseudomonas 
aeruginosa and to monitor newly approved antimicrobial 
agents, including ceftolozane-tazobactam and imipenem-rel-
ebactam [8,9]. 
Spain has participated in the SMART program since its ini-
tiation and several publications have summarized resistance in 
Enterobacterales and trends in ESBL producers [10-14]. In this 
article we present data on the activity of ceftolozane-tazobac-
tam, a new beta-lactam-beta-lactamase inhibitor combination 
[15], in comparison with other antimicrobial drugs used in IAI, 
UTI, RTI, and BSI in SMART isolates recovered in the 2016-2018 
period in Spain. 
MATERIAL AND METHODS
Microorganisms and participating centres. 
Consecutive unselected aerobic and facultative Gram-negative 
bacilli were obtained from 2016 to 2018 in 11 participating 
Spanish Hospitals (2016: Clínico de San Carlos, Madrid; Virgen 
Macarena, Seville; Marqués de Valdecilla, Santander; Basurto, 
Bilbao; Clínico Lozano Blesa, Zaragoza; 2016 to 2018: Ramón y 
Cajal, Madrid; Bellvitge, Barcelona; Gregorio Marañón, Madrid; 
La Fe, Valencia; Virgen del Rocío, Seville; and Son Espases, 
Palma de Mallorca). Each site collected up to the indicat-
ed number of isolates (one isolate per species and patient to 
avoid duplicates): 100 from IAI, 100 from RTI and 50 from UTI 
in 2016; 75 from IAI, 100 from RTI, and 75 from UTI in 2017; 
and 50 from IAI, 100 from RTI, 50 from UTI and 50 from blood 
in 2018. 
Peritoneal fluid (23%) was the most frequent intra-ab-
dominal sample followed by gall bladder (20%) samples. 
Actividad antimicrobiana de  
ceftolozano-tazobactam en Enterobacterales 
y Pseudomonas aeruginosa en el programa 
de vigilancia SMART (Study for Monitoring 
Antimicrobial Resistance Trends) en España 
(2016-2018)
RESUMEN 
Objetivo. Analizar la sensibilidad a ceftolozano-tazobac-
tam y antimicrobianos comparadores en Enterobacterales y 
Pseudomonas aeruginosa procedentes de infecciones intraab-
dominales (IIA), urinarias (ITU) y respiratorias (ITR) y bacterie-
mias del estudio SMART (Study for Monitoring Antimicrobial 
Resistance Trends). 
Métodos. Se analizó (EUCAST-2020) la sensibilidad de 
5.351 aislados recogidos en 11 hospitales españoles (2016-
2018) mediante microdilución en caldo y se estudió fenotípi-
camente la presencia de betalactamasas de espectro extendido 
(BLEE). En aislados resistentes a ceftolozano-tazobactam y/o 
carbapenémicos se caracterizaron las BLEE y carbapenemasas. 
Resultados. Escherichia coli fue el patógeno más fre-
cuente (49,3% IIA, 54,9% ITU, 16,7% ITR y 50% bacteriemia), 
seguido de Klebsiella pneumoniae (11,9%, 19,1%, 13,1% y 
15,4%, respectivamente). P. aeruginosa se aisló en el 9,3%, 
5,6%, 32% y 9%, respectivamente. La frecuencia de aislados 
con BLEE (2016-2017) fue: 30,5% K. pneumoniae, 8,6% E. coli, 
2,3% Klebsiella oxytoca y 0,7% Proteus mirabilis. Ceftolozano-
tazobactam fue muy activo en E. coli no productor (sensibi-
lidad 99,3%) y productor de BLEE (95,2%) y menos activo en 
K. pneumoniae (98% y 43,1%, respectivamente). CTX-M-15 
fue la BLEE más prevalente en E. coli (27,5%) y K. pneumoniae 
(51,9%) frecuentemente asociada con OXA-48-like. Un 93% de 
los aislados de P. aeruginosa fueron sensibles a ceftolozano-
tazobactam, que mantuvo su actividad (>75%) en aislados re-
sistentes a otros betalactámicos excepto en los resistentes a 
meropenen o ceftazidima-avibactam. GES-5, PER-1, VIM-1/2 
fueron las enzimas más prevalentes en aislados resistentes a 
ceftolozano-tazobactam. 
Conclusiones. Ceftolozano-tazobactam mostró elevada 
sensibilidad frente a los aislados del estudio SMART, aunque 
disminuyó en K. pneumoniae y P. aeruginosa con BLEE y/o car-
bapenemasas.
Palabras clave: Ceftolozano-tazobactam, Enterobacterales, Pseudomonas 
aeruginosa, estudio de vigilancia. 
INTRODUCTION
Over the last years health authorities and professionals 
have alerted of the worrisome increase of antimicrobial re-
sistance as well as its consequences in term of sanitary costs, 
management of the patients and mortality [1-3]. Different 
documents, including, among others, the Global Action 
Plan on Antimicrobial Resistance from the World Health 
Organization (WHO) [4], the Interagency Coordination Group 
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non-susceptible to ceftolozane-tazobactam (MIC >4/4 mg/L) 
and/or imipenem (MIC >2 mg/l) and/or imipenem-relebactam 
(MIC >2/4 mg/L) (data of imipenem-relebactam not shown). 
Screening of the resistance genes was performed as de-
scribed previously by multiplex PCR and sequencing and in-
clude the following β-lactamase genes: class A ESBLs (TEM, 
SHV, CTX-M, VEB, PER, and GES); class C plasmid AmpC (ACC, 
ACT, CMY, DHA, FOX, MIR, MOX), and carbapenemases [KPC, 
GES (class A), NDM, IMP, VIM GIM, SPM (class B, MBLs), OXA-
48-like (Enterobacterales only) and OXA-24-like (P. aeruginosa 
only) (class D)] [19,20]. Rates of carbapenemase-positive iso-
lates were calculated based on data available for molecularly 
characterized isolates.
Statistical analysis. Comparison of different frequencies 
were performed using the chi-squared test (χ2) taking P<0.05 
as statistically significant.
RESULTS
Bacterial distribution. Over the three-year period (2016-
2018), a total of 5,351 isolates were collected in the Spanish 
participating centers in the SMART study. Breakdown by type 
of infection is shown for 5,334 in table S1 (supplementary 
material) as 0.3% of the isolates were excluded in this analy-
sis but not in the susceptibility and molecular studies as their 
specimen source was not provided. Enterobacterales (n=4,151) 
constituted 77.8% of the total isolates, with E. coli in this 
group being the most frequently isolated microorganism 
(48.8%), followed by Klebsiella spp. (26.4%). The other Gram-
negative bacilli (1,183, 22.2%) were mostly non-fermenters, 
being P. aeruginosa the most frequent (77.9%) followed by 
Stenotrophomonas maltophilia (12.4%). As expected, relevant 
differences regarding the infection site were observed, being E. 
coli isolates more relevant in UTI (54.9%) than in other infec-
tion sites (range 16.7-50.0%) and P. aeruginosa isolates in RTI 
(32.0%) than in the others (range 5.6-9.3%).
Antimicrobial activity and phenotypic ESBL production 
in Enterobacterales. Table 1 shows the susceptibility profile 
of different antimicrobials tested against the most common 
Enterobacterales species. Overall, ceftolozane-tazobactam sus-
ceptibility (isolates categorized as S plus I) ranged from 79.4% 
to 100%. Of note, susceptibility was higher for ceftolozane-ta-
zobactam than for piperacillin-tazobactam (range 72.7-99.5%) 
or amoxicillin-clavulanate (range 66.5-85.5%) and similar or 
slightly inferior than that of ceftazidime-avibactam (97.7-
100.0%). Antibiotics for which all different frequent species 
demonstrated susceptibilities higher than 90% were colistin, 
amikacin, imipenem and meropenem (Table 1). 
In the 2016 and 2017 years, the presence of ESBLs was 
studied phenotypically in 2,298 Enterobacterales (1,447 E. coli, 
704 Klebsiella spp. and 147 Proteus mirabilis), of which 303 
(13.1%) presented this phenotype. Figure S1 (supplementary 
material) shows the distribution of ESBL producers, also in-
cluding information by infection site. The highest frequency 
was found in K. pneumoniae (30.5%, 174/571), followed by 
Almost 100% of the samples were from urine in patients with 
UTI. Regarding RTI, sputum (26%) was the most frequent sam-
ple. Isolates were identified at the species level in each hospital 
and sent to a central laboratory [IHMA (International Health 
Management Associates, Inc., Schaumburg, IL, USA)] to confirm 
the identification and determine the susceptibility to ceftolo-
zane-tazobactam and comparator antimicrobial agents. All the 
results were included in a centralized database. Patient’s age 
was also included. Moreover, following the standard criteria 
of the Centers for Disease Control and Prevention (CDC), the 
organisms were also rated as associated with a community-ac-
quired infection (isolates obtained within 48 h after hospitali-
zation) or with a nosocomial-infection (isolates obtained after 
48 h of hospital stay) [16].
Antimicrobial susceptibility and interpretive crite-
ria. Broth microdilution following the standard ISO recom-
mendations was performed at the central laboratory (IHMA) 
using MicroScan microdilution panels (Beckman, West 
Sacramento, CA, USA). The antimicrobials and range of con-
centrations (mg/L) tested were: piperacillin-tazobactam (2/4-
64/4), ceftriaxone (1-8), ceftazidime (1-16), cefepime (1-16), 
ceftolozane-tazobactam (0.125/4-1/4), ceftazidime-avibac-
tam (0.125/4-0.5/4), aztreonam (1-16), imipenem (0.125-4), 
meropenem (0.125-0.5), ertapenem (0.06-4), amikacin (4-16), 
colistin (1-2), ciprofloxacin (0.25-2) and levofloxacin (0.5-
4). Susceptibility to amoxicillin-clavulanic acid (2/2-256/2) 
was performed with a MIC gradient strip (Etest®, bioMérieux, 
Lyon, France). Escherichia coli ATCC 25922, E. coli ATCC 35218, 
Klebsiella pneumoniae ATCC 700603 (positive control for ESBL) 
and P. aeruginosa ATCC 27853 were used as quality control 
strains. All MIC results were interpreted using EUCAST rec-
ommendations [17]. When isolates were categorized as “I” 
(formerly “intermediate” and now indicating “susceptible, in-
creased exposure”), the percentage of “I” isolates were collated 
with “S” isolates (“susceptible, standard dose”) and presented 
as susceptible.
Phenotypic and molecular characterization of ESBL 
and carbapenemases. Production of ESBL in 2016 and 2017 
was phenotypically inferred in E. coli, Klebsiella spp. and 
Proteus mirabilis following CLSI criteria [19]. In 2018, ESBLs 
were not phenotypically investigated. Additionally, the pres-
ence of ESBL and carbapenemase genes were characterized 
molecularly in all E. coli and Klebsiella spp. isolates that were 
non-susceptible to ertapenem (MIC >0.5 mg/L) and/or ceftolo-
zane-tazobactam (MIC >2/4 mg/L) as well as in approximately 
50% of isolates susceptible to ertapenem, imipenem and/or 
ceftolozane-tazobactam that were non-susceptible to one or 
more of the following antibiotics: ceftriaxone (MIC >1 mg/L), 
cefepime (MIC >2 mg/L), ceftazidime (MIC >4 mg/L), and azt-
reonam (MIC >4 mg/L). These criteria were slightly modified in 
2017 and 2018 and ESBL and carbapenemase characterization 
was restricted to isolates from these species non-susceptible 
to ertapenem (MIC >0.5 mg/L), imipenem (MIC >1 mg/L) and/
or imipenem-relebactam (MIC >1/4 mg/L) and/or ceftolo-
zane-tazobactam (MIC >2/4 mg/L). In P. aeruginosa isolates, 
ESBL and carbapenemase genes were characterized in isolates 
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Microorganisms Percentage of susceptible (S+I)a isolates
AMC (≤8/4) PTZ (≤16/4) CTX (≤2) CAZ (≤4) FEP (≤4) ATM (≤4) CTZ (≤2/4) CZA (≤8/4) IMP (≤4) MEM (≤8) ETP (≤0.5) CIP (≤0.5) LVX (≤1) AMK (≤8) COL (≤2)
Escherichia coli 79.4 92.6 89.9 91.4 92.7 90.3 99.2 100.0 100.0 100.0 99.2 67.7 68.5 98.4 99.5
Klebsiella pneumoniae 66.5 72.7 67.6 71.1 71.9 71.6 83.7 100.0 97.1 97.6 85.6 65.0 70.2 99.0 94.9
Klebsiella oxytoca 83.0 89.4 97.7 97.2 97.8 91.1 97.2 97.8 99.4 99.4 98.3 95.5 96.1 100.0 100.0
Proteus mirabilis 85.5 99.5 96.6 99.1 100.0 100.0 99.1 100.0 98.6 100.0 100.0 59.2 64.2 99.1 --b
Enterobacter cloacae --b 78.8 70.8 75.5 89.2 78.4 81.3 95.7 97.5 97.9 85.1 86.3 87.1 100.0 90.9
Citrobacter freundii --b 77.9 66.1 67.6 97.1 73.5 79.4 100.0 97.1 97.1 97.1 92.6 91.2 100.0 100.0
Morganella morganii --b 98.9 83.1 86.8 97.8 96.7 100.0 100.0 100.0 100.0 100.0 63.7 75.8 100.0 --b
Serratia marcescens --b 95.9 92.1 98.8 98.8 98.8 97.6 97.7 95.9 99.4 97.1 91.8 93.5 98.8 --b
Table 1  Activity of different antimicrobial agents against most common Enterobacterales species collected in 
Spain in the SMART study (2016-2018)
aS = susceptible, standard dose, I = susceptible, increased exposure, EUCAST criteria except AMC in which CLSI criteria were considered; bThis species is considered intrinsi-
cally resistant to this antimicrobial; AMC: amoxicillin-clavulanic acid, PTZ: piperacillin-tazobactam, CTX: cefotaxime, CAZ: ceftazidime, FEP: cefepime, ATM: aztreonam, CTZ: 
ceftolozane-tazobactam, CZA: ceftazidime-avibactam, IMP: imipenem, MEM: meropenem, ETP: ertapenem, CIP: ciprofloxacin, LVX: levofloxacin, AMK: amikacin, COL: colistin
E. coli (8.6%, 125/1447) and Klebsiella oxytoca (2.3%, 3/130), 
being irrelevant in P. mirabilis (0.7%, 1/147). The percentage 
of ESBL-producing K. pneumoniae was higher in UTI (32.7%, 
67/205) than in the other locations. In E. coli the highest rate 
was present in RTI (12.2%, 29/237). 
Overall, ESBL production was significantly associated 
with nosocomial infections when compared with those ac-
quired in the community in isolates with this information for 
K. pneumoniae (33.7%, 142/421 vs. 21.3%, 32/150, P=0.004) 
but not for E. coli (9.7%, 74/690 vs. 7.5%, 51/678, P=0.144). 
Moreover, an increase of ESBL production was observed both 
in K. pneumoniae (<30 years: 21.9%, 9/41; 30-60 years: 25.4%, 
43/169; >60 years: 51.0%, 122/361. P<0.001) and E. coli (<30 
years: 4.2%, 7/171; 30-60 years: 7.3%, 29/425; >60 years: 
11.6%,89/850. P=0.07) with the increasing of age in patients. 
The activity of ceftolozane-tazobactam and other antimi-
crobials against E. coli and K. pneumoniae non-ESBL and ESBL 
producers recovered in 2016 and 2017 is shown in Figure S2 
(supplementary material). Figure 1 shows ceftolozane-tazo-
bactam MIC distribution of these organisms. This combina-
tion was very active in both E. coli non-ESBL (99.3% suscep-
tible) and ESBL (95.2% susceptible) producers. The activity of 
ceftolozane-tazobactam was similar or close to that of carbap-
enems, amikacin, and colistin. On the contrary, the presence of 
ESBL in K. pneumoniae was associated with a reduction in the 
activity of ceftolozane-tazobactam (98% vs. 43.1% suscepti-
ble); nevertheless, it was less affected than piperacillin-tazo-
bactam (90.2% vs. 25.9% susceptible) or amoxicillin-clavula-
nate (84.1 vs. 25.1% susceptible). As expected, the presence of 
ESBL dramatically affected the activity of extended spectrum 
cephalosporins and was associated with a decreased suscep-
tibility of ciprofloxacin both in E. coli and K. pneumoniae iso-
lates (Figure S2).
Table 2 analyses the activity of ceftolozane-tazobac-
tam in E. coli and K. pneumoniae non-ESBL and ESBL pro-
ducers that are resistant to different antibiotics. In E. coli, 
ceftolozane-tazobactam was active against more than 80% 
of isolates that were resistant to amoxicillin-clavulanate, 
piperacillin-tazobactam, meropenem or ciprofloxacin both 
in non-ESBL and ESBL producers. This activity was lower in 
ESBL-producing K. pneumoniae isolates that were resistant 
to these antimicrobial agents. Resistance to meropenem in 
these isolates denotes coproduction of carbapenemases in 
which ceftolozane-tazobactam is not active and all of them 
were categorized as resistant. 
Antimicrobial activity in P. aeruginosa. The antibiot-
ic susceptibility profile of P. aeruginosa is shown in Table 3. 
The behaviour of ceftolozane-tazobactam was excellent; only 
7.0% of the 925 isolates studied were resistant to this antibi-
otic. Regarding the percentage of susceptible isolates (S+I), the 
most active antimicrobials were colistin (99.3%), followed by 
amikacin (94.6%), ceftazidime-avibactam (94.0%) and ceftolo-
zane-tazobactam (93.0%). The least active compounds were 
the fluoroquinolones with susceptible figures of 63.5% for cip-
rofloxacin and 56.0% for levofloxacin. The activity of ceftolo-
zane-tazobactam was not compromised by infection site with 
93.1%, 93.0%, 92.9% and 92.6% of the IAI, UTI, RTI and BSI 
isolates susceptible to this antibiotic. Overall MIC distribution 
for this antibiotic can be observed in figure 2. 
Table 4 shows the activity of ceftolozane-tazobactam in P. 
aeruginosa isolates resistant to different beta-lactams, includ-
ing multidrug resistant ones. The activity of ceftolozane-tazo-
bactam ranged from 75.4% to 80.8%, except for isolates that 
were resistant either alone or combined to meropenem and 
ceftazidime-avibactam, denoting the potential involvement of 
carbapenemase associated resistance mechanisms [21].
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Escherichia coli Negative (318)a AMCa 52 (16.3) 50 (96.1) 2 (3.9)
Positive (29)a 16 (55.1) 14 (87.5) 2 (12.5)
Negative (1322) P/T 85 (6.4) 78 (91.7) 7 (8.3)
Positive (125) 23 (18.4) 19 (82.6) 4 (17.4)
Negative (1322) MER 0 (0) -- --
 Positive (125) 0 (0) -- --
Negative (1322) CIP 331 (25) 325 (98.2) 6 (1.8)
Positive (125) 110 (88) 106 (96.4) 4 (3.6)
Klebsiella pneumoniae Negative (62)a AMCa 5 (8.0) 5 (100) 0 (0)
Positive (19)a 9 (47.3) 3 (33.3) 6 (66.6)
Negative (397) P/T 39 (9.8) 31 (79.5) 8 (20.5)
Positive (174) 129 (74.1) 32 (24.8) 97 (75.2)
Negative (397) MER 5 (1.2) 0 (0) 5 (100)
 Positive (174) 11 (6.3) 0 (0) 11 (100)
Negative (397) CIP 48 (12.0) 41 (85.4) 7 (14.6)
Positive (174) 164 (94.2) 69 (42.1) 95 (57.9)
Table 2  Activity of ceftolozane-tazobactam in non-ESBL and ESBL producing 
Escherichia coli and Klebsiella pneumoniae isolates resistant to amoxicillin/
clavulanate (AMC), piperacillin/tazobactam (P/T), meropenem (MER) and 
ciprofloxacin (CIP) in the SMART study (2016 and 2017) in Spain.
aAMC: data are only from 2017
Figure 1  MIC distribution of ceftolozane-tazobactam in non-ESBL and ESBL producing Escherichia coli (A) 
and Klebsiella pneumoniae (B) isolates recovered in Spain in the SMART study (2016 and 2017). 
Ceftolozane-tazobactam susceptibility was calculated using EUCAST-2020 breakpoints [18]. 
Breakpoints are indicated with a line.
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DISCUSSION 
Surveillance studies have been highlighted as an impor-
tant tool to address the problem of antimicrobial resistance 
both at local and global levels [4-6,22]. The SMART study 
had monitored the activity of ertapenem in IAI since 2002 
but now it is also including ceftolozane-tazobactam suscep-
tibility, expanding the focus to UTI, RTI and BSI [8]. In this 
publication we present, for the first time in the SMART pro-
gram, specific data of ceftolozane-tazobactam susceptibili-
ty in isolates recovered in Spain from 2016 to 2018. Other 
publications of this international surveillance program have 
evaluated the activity of this antibiotic in isolates recovered 
from Asia Pacific region, including Taiwan [23,24], Brazil [25) 
and the US [8,9,26]. To note, we analysed the Spanish data 
using the new EUCAST criteria for ceftolozane-tazobactam 
published in 2020 (Enterobacterales, susceptible ≤2/4 mg/L 
and resistant >2/4 mg/L; P. aeruginosa, susceptible ≤4/4 
mg/L and resistant >4/4 mg/L) [17]. 
E. coli and K. pneumoniae susceptibility to ceftolozane-ta-
zobactam in Spain (99.2% and 83.7%, respectively) was slight-
ly higher than that in Taiwan (96.5% and 80.7%, respectively) 
[24] and the US (94.0% and 78.3% respectively [26]. In Europe, 
the activity of ceftolozane-tazobactam has been also moni-
tored in UTI and IAI in the PACTS surveillance study (Program 
to Assess Ceftolozane/Tazobactam Susceptibility) but had used 
the previous EUCAST breakpoint for Enterobacterales [27]. 
Nevertheless, whole MIC distributions were presented in this 
publication allowing comparison with our results. In the PACTS 
study ceftolozane-tazobactam susceptibility was slightly lower 
Molecular characterization of ESBLs and carbapen-
emases. Molecular studies for ESBLs and carbapenemases 
were performed in 80 E. coli, 160 K. pneumoniae and 267 P. 
aeruginosa isolates (Table S2 and S3 supplementary material). 
In E. coli, CTX-M-15 (27.5%, 22/80), either alone or with an-
other enzyme, including carbapenemases, was the most prev-
alent ESBL, followed by CTX-M-27 (8.7%, 7/80), SHV-12 (7.5%, 
6/80), and CTX-M-14 (6.2%, 5/80). The most prevalent carbap-
enemase in this species was OXA-48-like (11.2%, 9/80) mainly 
present in ceftolozane-tazobactam susceptible isolates. Highly 
resistant isolates (MIC >8/4 mg/L) frequently presented combi-
nations of different enzymes being two of them a VIM-1 and a 
KPC-type carbapenemase. To note that one ceftolozane-tazo-
bactam susceptible E. coli isolate (CMI=0.25/4 mg/L) presented 
a KPC-3 enzyme. 
In K. pneumoniae, the situation was more complex than in 
E. coli (Table S2) The most prevalent ESBL was also CTX-M-15 
(51.9%, 83/160), in most cases associated with OXA-48-like 
(n=61). SHV-12 was also prevalent (18.1%, 29/160), also asso-
ciated with OXA-48-like (n=15). Ceftolozane-tazobactam re-
sistant isolates normally presented with 2 or 3 enzymes. KPC-
3 and metallo-beta-lactamases (VIM-1 or NDM-1) were only 
present in highly resistant ceftolozane-tazobactam resistant 
isolates (MIC >8/4 mg/L).
Finally, in P. aeruginosa isolates (Table S3), PER-1 (0.7%, 
2/267) and GES-5 (0.7%, 2/267) enzymes were scarcely found. 
Metallo-beta-lactamases (VIM-1, VIM-2, VIM-20 and IMP-13) 
were present in 8.6% (23/267) of the isolates. KPC were not 
found, but one isolate had a CTX-M-2 ESBL. 






Piperacillin-tazobactam 925 ≤2/4 - >64/4 8/4 >64/4 -- 66.8 33.2
Ceftazidime 925 ≤ 1 - >32 4 >32 -- 71.8 28.2
Cefepime 925 ≤ 1 - >32 4 32 -- 72.3 27.7
Ceftolozane-tazobactam 925 ≤ 0.12/4 - >32/4 1/4 4/4 93.0 -- 7.0
Ceftazidime-avibactama 217 ≤ 0.12/4 - >32/4 2/4 8/4 94.0 -- 6.0
Aztreonam 925 ≤ 1 - >16 8 >16 -- 79.7 20.3
Imipenem 925 ≤0.12 - >32 1 16 -- 75.5 24.5
Meropenem 925 ≤ 0.12 - >32 0.5 16 74.7 14.0% 11.3
Tobramycina 217 <= 0.5 - >8 ≤ 0.5 >8 77.4 -- 22.6
Amikacin 925 ≤4 - >32 ≤4 8 94.6 -- 5.4
Ciprofloxacin 925 ≤0.25 - >2 ≤0.25 >2 -- 63.5 36.5
Levofloxacin 925 ≤0.5 - >4 ≤1 >4 -- 56.0 44.0
Colistin 925 ≤1 - >4 ≤1 ≤1 99.3 -- 0.7
aData are only for 2018
Table 3  Activity of different antimicrobials against Pseudomonas aeruginosa collected in Spain in 
the SMART study (2016-2018)
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SMART analyses [13,14], with CTX-Ms being the most impor-
tant ESBLs. Regarding carbapenemases, their presence in E. coli 
and K. pneumoniae isolates was also relevant, particularly in K. 
pneumoniae isolates. OXA-48-like was the most prevalent car-
bapenemases in E. coli (11.2%, 9/80) and K. pneumoniae (55%, 
88/160) isolates, followed by metallo-beta-lactamases (1.2%, 
1/80 and 4.4%, 7/160, respectively) and KPCs (1.2%, 1/80 and 
3,1%, 5/160, respectively). This situation is also reflected in 
other studies performed in Spain in which carbapenemases 
have been characterized [29-31].
In our study, the reduction of ceftolozane-tazobactam 
(98.8% E. coli and 82.1% K. pneumoniae) than that obtained in 
the analysis of the SMART Spain database. We also performed 
the SUPERIOR study in Spain in which we evaluated the activ-
ity of ceftolozane-tazobactam in isolates recovered from UTI 
and IAI in ICU patients. Reanalysing the SUPERIOR data using 
2020 EUCAST criteria, the susceptibility to this antibiotic was 
96.2% in E. coli and 72.6% in Klebsiella spp. [28]. 
The SMART study also monitors ESBL trends and, more 
recently, carbapenemases. We confirm in the present analysis 
an increase in the prevalence of ESBLs in Spain in K. pneumo-
niae and maintenance in E. coli when compared with previous 
Antimicrobial resistance No. of isolates No. of resistant isolates (%) No. of ceftolozane susceptible isolates (%)
Piperacillin-tazobactam 925 307 (33.2) 248 (80.8)
Ceftazidime 925 261 (28.2) 199 (76.3)
Cefepime 925 256 (27.7) 193 (75.4)
Imipenem 925 227 (24.5) 174 (76.7)
Meropenem 925 105 (11.3) 58 (55.3)
Ceftazidime-avibactama 217 13 (5.9) 4 (30.8)
Piperacillin-tazobactam, ceftazidime 925 243 (26.2) 187 (77.0)
Imipenem, meropenem 925 99 (10.7) 55 (55.5)
Piperacillin-tazobactam, ceftazidime, meropenem 925 75 (8.1) 33 (44.0)
Piperacillin-tazobactam, ceftazidime, imipenem, meropenem 925 72 (7.7) 33 (45.9)
Piperacillin-tazobactam, ceftazidime, imipenem, meropenem, ceftazidime-avibactam 217 9 (4.1) 2 (22.3)
Table 4  Ceftolozane-tazobactam activity in P. aeruginosa isolates resistant to different antimicrobials, 
including multidrug resistant ones. 
aData are only for 2018
Figure 2  MIC distribution of ceftolozane-tazobactam in Pseudomonas 
aeruginosa isolates recovered in Spain in the SMART study 
(2016-2018). Ceftolozane-tazobactam susceptibility was 
calculated using EUCAST-2020 breakpoints [18]. Breakpoints 
are indicated with a line.
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providing access to the database of the SMART epidemiolog-
ical surveillance study and molecular data.
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Espases, Mallorca); E. Cercenado (Hospital Universitario 
Gregorio Marañón, Madrid); F.J. Castillo and C. Seral (Hospital 
Clínico Universitario Lozano Blesa, Zarago za); R. Figueroa and 
R. Cisterna (Hospital Basurto, Bilbao); L. Gálvez-Benítez, I. 
Pupo-Ledo and A. Rodríguez-Villodres (Hospital Universitario 
Virgen del Rocío, Sevilla); F. González Romo and A. Delgado 
Iribarren (Hospital Clínico San Carlos, Madrid); A. Hernández-
Cabezas, M. Bosch Alepuz and J.L. López-Hontangas (Hospital 
Universitario y Politécnico La Fe, Valencia); J. Rodriguez-
Lozano and J. Calvo (Hospital Universitario Marqués de 
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